MarketPeel
Insider Trading Intelligence
SQ

Steven C. Quay

ATOS
PRESIDENT & CEO · ATOSSA THERAPEUTICS, INC. · CIK 0001008227
FILING MIX · LIFETIME100%/0%
BUYS
14
SELLS
0
TOTAL VALUE
$1.16M
COMPANIES
1
ACTIVE SINCE
Apr 2020
HOLDINGS NOW
88,038
AVG SELL PX
TRADE KIND
SHOWING 14 / 14
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 1 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Steven C. Quay, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+0.00%-6.90%+0.84%-7.73%-7.73%
14d1+0.00%-1.15%+2.24%-3.39%-3.39%
30d1+0.00%-9.20%+1.96%-11.15%-11.15%
60d1+0.00%-2.30%+7.88%-10.18%-10.18%
90d1+0.00%-13.79%+9.77%-23.56%-23.56%
180d1+0.00%-9.20%+14.21%-23.40%-23.40%
1y1+0.00%-62.91%+27.36%-90.27%-90.27%
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ATOS · 88,038 shares · as of Mar 27, 2026
0475,000950,0001,425,0001,900,000202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 14 buys / 0 sellsCOVERAGE · 24 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
65,00088,038Mar 27, 2026Mar 31, 2026View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
950,000$0.60$572.9K950,000Jan 20, 2026Jan 22, 2026View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
325,203339,101Jan 20, 2026Jan 22, 2026View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
331,674345,572Jan 20, 2026Jan 30, 2026View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
950,000$0.60$572.9K950,000Jan 20, 2026Jan 30, 2026View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASE
President & CEO
11,239$0.88$9.9K13,898May 21, 2025May 22, 2025View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,366,0621,366,062May 15, 2025May 16, 2025View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,795,1001,795,100Jun 27, 2024Jul 1, 2024View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,873,1001,873,100Mar 2, 2023Mar 6, 2023View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,900,0001,900,000Feb 24, 2022Feb 28, 2022View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,900,0001,900,000May 14, 2021May 18, 2021View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,900,0001,900,000May 14, 2021May 18, 2021View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,305,0001,305,000Apr 9, 2020Apr 13, 2020View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
195,000195,000Apr 9, 2020Apr 13, 2020View →
Other insiders · ATOS
Loading peer insiders…
About this filer
CIK 0001008227
ROLE
President & CEO
PRIMARY
ATOS
COMPANIES
1
ACTIVE SINCE
Apr 2020
MARKETPEEL · /INSIDER/0001008227DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback